European Pharmaceutical Review

MARCH 14, 2024

To mark World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics, spoke with EPR about the challenges of treating kidney diseases, specifically IgAN, a condition caused by dysfunctional B cells. Individuals who receive corticosteroids may experience limited efficacy, alongside significant side effects.

Food and Drug Administration 98

Food and Drug Administration Patients Leads Side effects 98

European Pharmaceutical Review

MARCH 14, 2024

To mark World Kidney Day 2024, Dr Marshall Fordyce, CEO of Vera Therapeutics, spoke with EPR about the challenges of treating kidney diseases, specifically IgAN, a condition caused by dysfunctional B cells. Individuals who receive corticosteroids may experience limited efficacy, alongside significant side effects.

Food and Drug Administration 98

Food and Drug Administration Patients Leads Side effects 98

Clarivate

MAY 1, 2024

We took a look at these drugs’ impact on the medtech sector for our forthcoming report, Medtech Trends to Watch in 2024 , and found a more nuanced picture. Device-based treatments for comorbidities associated with obesity will also see an impact. You can register for the webinar here.

Side effects 59

Side effects Physicians Medical Patients 59

European Pharmaceutical Review

NOVEMBER 5, 2024

New data presented at Psych Congress 2024 has shown that the olanzapine long-acting injectable (LAI) TEV-‘749 / mdc-TJK demonstrated “significant improvement” in social functioning and quality of life in adults with schizophrenia. This was based on findings from the initial period (up to week 8) of the Phase III SOLARIS trial.

Side effects 52

Side effects Safety Medical Medicine 52

Pharmaceutical Technology

JUNE 16, 2023

This includes the company’s upcoming Phase IIIb trial, but also another Phase III study and a long-term safety trial, said ANeuroTech CEO Eric Buntinx in an interview with Pharmaceutical Technology. The company aims to run an interim analysis of the trial by mid-2024 at the very latest.

Food and Drug Administration 52

Food and Drug Administration Side effects Safety Recruitment 52

pharmaphorum

AUGUST 19, 2022

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid drugs. Along with knee osteoarthritis, Grünenthal also plans to test resiniferatoxin in other joints affected by the condition.

Side effects 52

Side effects Recruitment Patients Safety 52

PM360

SEPTEMBER 21, 2023

A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted. A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted.

Management 105

Management Manufacturing Sales Competition 105

PM360

JUNE 24, 2024

As we enter into the age of precision medicine, AI will be a critical tool to determine, with the help of disease knowledge graphs, which indications, associations, contraindications, side effects, genetic markers, drug targets, drug carriers, and interactions to take into account on a case-by-case basis. AI isn’t coming for your job.

Healthcare 52

Healthcare Healthcare Patients Side effects 52

pharmaphorum

JULY 26, 2022

Merck’s exit came after other companies including Pfizer, Eli Lilly and Roche all scrapped CETP development programmes following safety or efficacy issues. BROADWAY and BOOKLYN will generate data in 2024, with PREVAIL set to read to in 2026, and if the results are positive will be followed by filings in the US, Europe, China and Japan.

Side effects 52

Side effects Safety Pharma Patients 52

European Pharmaceutical Review

JULY 18, 2024

1 As they can be highly targeted in their action, they could become the treatment of choice for clinicians and patients due to the reduced risk of side effects. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy.

Food and Drug Administration 59

Food and Drug Administration Engineering Pharmacology Side effects 59

Pharmaceutical Representative Training

JUNE 22, 2024

The pharmaceutical industry is one of the most heavily regulated sectors due to the direct impact of its products on public health and safety. Several factors contribute to the stringent regulatory environment: Patient Safety: Ensuring that the pharmaceutical products are safe and effective is a crucial aspect. link] Reuters.

Sales 52

Sales Pharmaceutical Ethics Pharmaceutical Sales 52

PM360

OCTOBER 22, 2024

Understanding these effects is critical for payers in determining the true value of a treatment and how it should be positioned in their coverage plans. With older, established drugs, providers can leverage their own experience and insights gained from treating patients with those specific drugs.

Side effects 52

Side effects Patients Prescription Healthcare 52

PM360

OCTOBER 22, 2024

Pharmaceutical companies play a critical role in the design of packaging and labeling for medication, and we are working towards innovative ways to improve and prioritize patient safety, understanding, and adherence. Educational materials for patients, both print out and online, have been used to address common side effects.

Education 52

Education Side effects Medical Patients 52

Pharmaceutical Representative Training

OCTOBER 9, 2024

They may have valid concerns about the product’s cost, potential side effects, or its suitability for their patients. There are four main categories of objections, known as PETE: Price, Effort, Time, and Effectiveness. 2024, August 27). 2024, September 20). 2024, August 28). link] Jacoby, D.

Sales 52

Sales Pharma Pharmaceutical Sales Prospecting 52

Medico Reach

FEBRUARY 8, 2023

billion during 2020-2024. The Emergence of the Pharmacovigilance Market Medicines and vaccines often have unwanted and severe side effects. Such results call for stringent vigilance on the medicines quality and after-effects, nudging the emergence of the pharmacovigilance market. from 2023 to 2030. from 2023 to 2030.

Pharma 52

Pharma Medicine Marketing Prospecting 52

European Pharmaceutical Review

OCTOBER 3, 2024

It is highly selective and has shown an excellent safety and tolerability profile to date. Advancements in oral small molecule drug development can be attributed to significant technological improvements, particularly in screening methodologies, including AI -driven approaches, which help identify and profile drugs more effectively.

Safety 52

Safety Patients Pharmaceutical Side effects 52

Pharmaceutical Technology

FEBRUARY 17, 2023

In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. For this approach, a “3+3” model is used where a study enrolls three patients into a given dose cohort.

FDA 115

FDA Side effects Pharmacology Patients 115